Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided into immunomodulators, thrombopoietin-receptor agonists (TPO–RAs), and spleen tyrosine kinase inhibitors (Syk inhibitors). Systemic glucocorticoids and TPO–RAs are the pillars of clinical management; however, alternative therapies such as the Syk inhibitor fostamatinib (Rigel Pharmaceuticals’ Tavalisse) and the immunosuppressant rituximab provide additional options for refractory disease. This report offers insight from U.S. real-world claims data into current prescribing trends in ITP.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ITP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ITP patients?
• How have TPO–RAs and fostamatinib been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of ITP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of ITP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: TPO–RAs, Syk inhibitors, glucocorticoids, immunostimulants, immunosuppressants

Key analyses:

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Key features: Dashboard featuring interactive visuals, easy navigation, and expanded analyses